Cardiac dyssynchrony and response to cardiac resynchronisation therapy in heart failure: can genetic predisposition
1Department of Experimental Cardiology, Room K2-116, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Insights
Cardiac resynchronisation therapy (CRT) improves heart failure outcomes for many. However, genetic factors may influence patient response to CRT, explaining why some do not benefit from this treatment.
Area of Science:
- Cardiology
- Genetics
- Heart Failure Research
Background:
- Cardiac resynchronisation therapy (CRT) is a standard treatment for heart failure with reduced ejection fraction and ventricular dyssynchrony.
- While CRT benefits many patients, a significant portion do not experience clinical improvement.
- This highlights a need to understand factors influencing CRT response.
Purpose of the Study:
- To review the potential role of genetic factors in modulating patient response to CRT.
- To summarize existing genetic studies investigating variations in candidate genes related to CRT outcomes.
Main Methods:
- Literature review of studies examining genetic variations and CRT response.
- Focus on candidate gene approaches in heart failure patients undergoing CRT.
Main Results:
- Evidence suggests genetic variations may influence individual responses to CRT.
- Few studies have explored this, indicating a gap in current research.
- Candidate gene analysis is a primary method used.
Conclusions:
- Genetic factors are a plausible explanation for non-response to CRT in some heart failure patients.
- Further research into the genetic underpinnings of CRT response is warranted.
- Identifying genetic markers could personalize CRT eligibility and improve outcomes.
Abstract:
Cardiac resynchronisation therapy (CRT) is an accepted treatment for heart failure patients with depressed left ventricular (LV) function and dyssynchrony. However, despite better clinical outcome and improved cardiac function after CRT in the majority of eligible heart failure patients, a large proportion of implanted patients do not seem to benefit clinically from this therapy. In this review we consider whether genetic factors may play a role in modulating response to CRT and summarise the few genetic studies that have investigated the role of genetic variation in candidate genes.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure VI: Adjunct Therapies
Cardiomyopathy V: Interprofessional Care
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure V: Medical Management


